Targeting GITR in cancer immunotherapy – there is no perfect knowledge

por Davar, Diwakar, Zappasodi, Roberta
Publicado 2023

MEK inhibitors for the treatment of NRAS mutant melanoma

por Sarkisian, Saro, Davar, Diwakar
Publicado 2018

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

por Davar, Diwakar, Zarour, Hassane M.
Publicado 2022

Adjuvant Therapy: Melanoma

por Davar, Diwakar, Tarhini, Ahmad, Kirkwood, John M.
Publicado 2011

Toll-Like Receptor 9 Agonists in Cancer

por Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
Publicado 2020

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV

por Davar, Diwakar, Wilson, Melissa, Pruckner, Chelsea, Kirkwood, John M.
Publicado 2015

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma

por Davar, Diwakar, Socinski, Mark A., Dacic, Sanja, Burns, Timothy F.
Publicado 2015

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

por Davar, Diwakar, Ding, Fei, Saul, Melissa, Sander, Cindy, Tarhini, Ahmad A., Kirkwood, John M., Tawbi, Hussein A.
Publicado 2017

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features

por Achkar, Tala, Arjunan, Ananth, Wang, Hong, Saul, Melissa, Davar, Diwakar, Appleman, Leonard J., Friedland, David, Parikh, Rahul A.
Publicado 2017

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

por Garcia, Christine A., El-Ali, Alex, Rath, Tanya J., Contis, Lydia C., Gorantla, Vikram, Drappatz, Jan, Davar, Diwakar
Publicado 2018

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

por Shaikh, Saba S., Zang, Yan, Hanmer, Janel, Wang, Hong, Lin, Yan, Davar, Diwakar, Zarour, Hassane M., Kirkwood, John M., Najjar, Yana G.
Publicado 2022

A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma

por Shaikh, Saba S., Yang, Xi, Fortman, Dylan D., Wang, Hong, Davar, Diwakar, Luke, Jason J., Zarour, Hassane, Kirkwood, John M., Najjar, Yana G.
Publicado 2022

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients

por Fortman, Dylan, Avellan, Maria G. Pazan, Hurd, Drew, Schwartz, Marc, Dubner, Howard, Hewitt, Corey, Berton, Samantha, Ernst, Scarlett, Rose, Amy, Zarour, Hong Wangd, Hassane, Davar, Diwakar
Publicado 2023

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

por Bastacky, Melissa L., Wang, Hong, Fortman, Dylan, Rahman, Zahra, Mascara, Gerard P., Brenner, Timothy, Najjar, Yana G., Luke, Jason J., Kirkwood, John M., Zarour, Hassane M., Davar, Diwakar
Publicado 2021

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study

por Augustin, Ryan C., Huang, Ziyu, Ding, Fei, Zhai, Shuyan, McArdle, Jennifer, Santisi, Anthony, Davis, Michael, Sander, Cindy, Davar, Diwakar, Kirkwood, John M., Delgoffe, Greg M., Warner, Allison Betof, Najjar, Yana G.
Publicado 2023

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

por Augustin, Ryan C, Newman, Sarah, Li, Aofei, Joy, Marion, Lyons, Maureen, Pham, Mary P, Lucas, Peter, Smith, Katelyn, Sander, Cindy, Isett, Brian, Davar, Diwakar, Najjar, Yana G, Zarour, Hassane M, Kirkwood, John M, Luke, Jason John, Bao, Riyue
Publicado 2023

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

por Davar, Diwakar, Zappasodi, Roberta, Wang, Hong, Naik, Girish S., Sato, Takami, Bauer, Todd, Bajor, David, Rixe, Olivier, Newman, Walter, Qi, Jingjing, Holland, Aliya, Wong, Phillip, Sifferlen, Lianna, Piper, Diane, Sirard, Cynthia A., Merghoub, Taha, Wolchok, Jedd D., Luke, Jason J.
Publicado 2022

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

por Ribas, Antoni, Medina, Theresa, Kirkwood, John M., Zakharia, Yousef, Gonzalez, Rene, Davar, Diwakar, Chmielowski, Bartosz, Campbell, Katie M., Bao, Riyue, Kelley, Heather, Morris, Aaron, Mauro, David, Wooldridge, James E., Luke, Jason J., Weiner, George J., Krieg, Arthur M., Milhem, Mohammed M.
Publicado 2021

Predicting cancer immunotherapy response from gut microbiomes using machine learning models

por Liang, Hai, Jo, Jay-Hyun, Zhang, Zhiwei, MacGibeny, Margaret A., Han, Jungmin, Proctor, Diana M., Taylor, Monica E., Che, You, Juneau, Paul, Apolo, Andrea B., McCulloch, John A., Davar, Diwakar, Zarour, Hassane M., Dzutsev, Amiran K., Brownell, Isaac, Trinchieri, Giorgio, Gulley, James L., Kong, Heidi H.
Publicado 2022

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes

por Karapetyan, Lilit, AbuShukair, Hassan M., Li, Aofei, Knight, Andrew, Al Bzour, Ayah Nedal, MacFawn, Ian P., Thompson, Zachary J., Chen, Ann, Yang, Xi, Dadey, Rebekah, Karunamurthy, Arivarasan, De Stefano, Danielle Vargas, Sander, Cindy, Kunning, Sheryl R., Najjar, Yana G., Davar, Diwakar, Luke, Jason J., Gooding, William, Bruno, Tullia C., Kirkwood, John M., Storkus, Walter J.
Publicado 2023